By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Otsuka America Pharmaceutical, Inc. 

2440 Research Boulevard

Rockville  Maryland  20850  U.S.A.
Phone: 301-990-0030 Fax: 301-212-8620

Otsuka is a successful, global group of affiliated companies that discovers, develops and markets innovative products. In the U.S., Otsuka is hard at work investigating potential new treatments, with numerous compounds in various stages of development to treat disorders of the cardiovascular, gastrointestinal, respiratory, renal and central nervous systems, and to treat cancer and ophthalmic disorders. Our pharmaceutical products include ABILIFY® (aripiprazole) Tablets and intramuscular injection, IV BUSULFEX® (busulfan) Injection and PLETAL® (cilostazol) Tablets, although we no longer actively market PLETAL. We also have the BreathTek™ Urea Breath Test for H. pylori. We have numerous additional products in our pipeline that are currently under development. We are highly diversified, with pharmaceutical as well as consumer products such as Crystal Geyser Water, NatureMade® Vitamins, Ridge Wines, and diagnostic equipment.

Please visit our website at for more information.

Key Statistics

Ownership: Subsidiary

Web Site: Otsuka America Pharma


Company News
Otsuka America Pharma's Abilify Can Cause Urges to Gamble, Eat, Shop, Have Sex: FDA 5/4/2016 8:17:35 AM
Otsuka America Pharmaceutical, Inc. Release: Results Of New Survey Show Nearly Two Thirds Of Surveyed Adults With Major Depressive Disorder (MDD) Who Report Taking Their Medication As Prescribed Still Experience Symptoms At Least Weekly 2/11/2016 8:40:04 AM
Otsuka America Pharmaceutical, Inc. Release: FDA Approves Deltoid Injection Site For Abilify Maintena (Aripiprazole) For Extended-Release Injectable Suspension In The Treatment Of Schizophrenia 7/30/2015 1:15:55 PM
Otsuka America Pharmaceutical, Inc. And Lundbeck Inc. (LUN.CO) To Present Data On Investigational Compound Brexpiprazole In Schizophrenia And Major Depressive Disorder At American Psychiatric Association Annual Meeting 5/13/2015 11:37:06 AM
H. Lundbeck A/S (LUN.CO) and Otsuka America Pharmaceutical, Inc. Release: Results Of Phase III Study Of Brexpiprazole In Adult Patients With Schizophrenia Published In American Journal Of Psychiatry 4/17/2015 7:40:06 AM
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S (LUN.CO) Release: U.S. FDA Accepts For Review Supplemental New Drug Application For Deltoid Administration Of Abilify Maintena® (Aripiprazole) Extended-Release Injectable Suspension 12/15/2014 10:13:44 AM
Otsuka America Pharmaceutical, Inc. And H. Lundbeck A/S (LUN.CO) Release: Aripiprazole Once-Monthly Injectable Shows Superior Effectiveness To Paliperidone Palmitate Once-Monthly Injectable On Quality Of Life Scale In Patients With Schizophrenia 11/3/2014 10:57:38 AM
European Medicines Agency Accepts Otsuka America Pharmaceutical, Inc.'s Marketing Authorisation Application (MAA) For Tolvaptan, An Investigational Compound For Autosomal Dominant Polycystic Kidney Disease (ADPKD) 12/27/2013 7:38:51 AM
Bristol-Myers Squibb Company (BMY) and Otsuka America Pharmaceutical, Inc. Release: Four-Year Data From Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) To Imatinib In First-Line Treatment Of Adults With Ph+ CP-CML Presented At Annual Meeting Of The American Society of Hematology 12/10/2013 6:56:26 AM
Almac Group Receives Appreciation Award From Otsuka America Pharmaceutical, Inc. 7/31/2013 9:54:30 AM